ECSP15025357A - SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS - Google Patents
SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMSInfo
- Publication number
- ECSP15025357A ECSP15025357A ECIEPI201525357A ECPI201525357A ECSP15025357A EC SP15025357 A ECSP15025357 A EC SP15025357A EC IEPI201525357 A ECIEPI201525357 A EC IEPI201525357A EC PI201525357 A ECPI201525357 A EC PI201525357A EC SP15025357 A ECSP15025357 A EC SP15025357A
- Authority
- EC
- Ecuador
- Prior art keywords
- ruxolitinib
- dosage forms
- sustained release
- useful
- pharmaceutically acceptable
- Prior art date
Links
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formulaciones de liberación sostenida y formas de dosificación de ruxolitinib o su sal farmacéuticamente aceptable, que son útiles en el tratamiento de enfermedades relacionadas con las quinasa Janus como trastornos mieloproliferativos.The present invention relates to sustained release formulations and dosage forms of ruxolitinib or its pharmaceutically acceptable salt, which are useful in the treatment of Janus kinase related diseases such as myeloproliferative disorders.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726893P | 2012-11-15 | 2012-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15025357A true ECSP15025357A (en) | 2017-07-31 |
Family
ID=72643859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201525357A ECSP15025357A (en) | 2012-11-15 | 2015-06-15 | SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP15025357A (en) |
-
2015
- 2015-06-15 EC ECIEPI201525357A patent/ECSP15025357A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150265A (en) | DOSAGE FORMS OF SUSTAINED RUXOLITINIB LIBERATION | |
| CY1124311T1 (en) | DNA-PK INHIBITORS | |
| CY1125436T1 (en) | DNA-PK INHIBITORS | |
| IL254353A0 (en) | Vaporizer to vaporize active ingredient | |
| CL2014001752A1 (en) | Substituted bicyclic compounds; pharmaceutical composition that includes them; and use in the treatment of diseases such as cancer, Alzheimer's, AIDS, among others. | |
| MX386935B (en) | PRODRUGS OF FUMARATES AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES. | |
| CR20150633A (en) | BIPIRAZOL DERIVATIVES AS JAK INHIBITORS | |
| UY33863A (en) | METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX2021000007A (en) | ENZALUTAMIDE FORMULATIONS. | |
| PE20150631A1 (en) | CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR | |
| BR112015009942A2 (en) | tricyclic fused thiophene derivatives as jak inhibitors | |
| BR112015020389A2 (en) | carbazole compounds useful as bromodomain inhibitors | |
| EA201590343A1 (en) | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | |
| UY33616A (en) | COMPOUNDS WITH IMIDAZOTRIAZINONA STRUCTURE | |
| EA201500365A1 (en) | COMBINATION OF REGORAPHENIBE AND ACETYLSALICYLIC ACID TO CURE CANCER | |
| MX2015009058A (en) | COMPOSITIONS AND METHODS TO TREAT CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES. | |
| EA201291211A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE | |
| CR20160290A (en) | AUTOTAXINE TETRACYCLIC INHIBITORS | |
| MX364704B (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| TR201908151T4 (en) | Isoindoline derivatives. | |
| UA112488C2 (en) | THREE (HETERO) ARILPYRAZOLES AND THEIR APPLICATIONS | |
| AR125919A2 (en) | SUSTAINED-RELEASE RUXOLITINIB DOSAGE FORMS | |
| CY1118255T1 (en) | Substituted 6-amino-nicotinamides which carry a group containing KCNQ2 / 3 modulators | |
| ECSP15025357A (en) | SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS | |
| MX375545B (en) | Pyridazinone derivatives as phosphoinositide 3-kinases inhibitors |